jeudi 8 mars 2018

Onco Actu du 8 mars 2018

3. Prévention

Vitamin D may offer protection against cancers, study says [The Guardian]

Dose of sunshine exposure could cut the risk of cancer by a fifth [The Telegraph]

3.6 Prévention - Activité physique

Testing an Interactive Approach to Promote Exercise in Young Cancer Survivors [NCI]

4. Dépistage, diagnostic et pronostic

Imaging agent helps predict success of lung cancer therapy [Stanford Medicine]

Cancer screening recommendations: an international comparison of high income countries [Public Health Reviews]

4.1 Dép., diag. & prono. - Prostate

Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer [Myriad]

4.9 Dép., diag. & prono. - Sein

Breast cancer screening guidelines may lead to delayed diagnosis in nonwhite women [Mass. General Hospital]

5.12.1 Immunothérapies - partenariats

Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate) [Merck]

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star [EndPoints]

Eisai clinches Merck deal to develop and sell cancer drug, shares soar [Reuters]

5.12.2 Immunothérapies - CAR-T

MD Anderson and Berkeley Lights launch Optera Therapeutics to accelerate development of cell therapies for cancer [MD Anderson]

5.2 Pharma

Roche promotes Pao to replace departing pRED head Reed [FierceBiotech]

Changes to the Roche Enlarged Corporate Executive Committee [Roche]

5.2.1 Pharma - Partenariats

Aptose signs $125M-plus BET inhibitor deal with Ohm Oncology [FierceBiotech]

Pfizer breaks off a 5-year, $635M collaboration deal with CytomX, with nothing to show for it [EndPoints]

5.4 Traitements - Economie

Cancer treatment guidelines questioned in new study [CNN]

Vinay Prasad on the NCCN’s cancer treatment guidelines: The US system needs an audit [BMJ Blogs]

US cancer network recommending expensive drugs based on weak evidence, study finds [The Guardian]

Capturing the Benefits of Competition for Patients [FDA]

FDA head Gottlieb criticizes industry for 'Kabuki drug-pricing' [Reuters]

6. Lutte contre les cancers

Tumors and Transformations [NEJM]

6.10.1 Politiques (USA)

How the ‘right-to-try’ movement muscled its way into Washington [STAT]

6.3 Associations/Fondations

Pharma backing of advocacy groups: a call for transparency [HealthNewsReview]

6.7 DMP, Big Data & applis

ASCO Launches New Website Focused on the Business of Oncology [ASCO in Action]